Literature DB >> 1899474

Dopa-responsive dystonia: long-term treatment response and prognosis.

T G Nygaard1, C D Marsden, S Fahn.   

Abstract

We report observations on the treatment of 66 patients with presumed dopa-responsive dystonia (DRD). Forty-seven of these patients had hereditary disease; 19 had disease of sporadic occurrence. Initial diagnostic confusion with "cerebral palsy" or "spastic diplegia" existed in 16 patients. Several patients benefited from anticholinergic medications and a few from carbamazepine. Levodopa was the most effective treatment in all cases. In the majority, there was an excellent response, with continued long-term clinical stability on levodopa therapy for as long as 10 to 22 years. Four men with sporadic disease and 1 woman with a sister affected with adolescent-onset parkinsonism had similar initial treatment response, but developed "wearing-off" and a less satisfactory response to levodopa within the first few years of treatment. This indicates that some patients with clinical syndromes suggestive of DRD may not have an excellent prognosis on long-term levodopa treatment and may represent misclassified cases of childhood-onset parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899474     DOI: 10.1212/wnl.41.2_part_1.174

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

1.  A splice mutation in the GTP cyclohydrolase I gene causes dopa-responsive dystonia by exon skipping.

Authors:  M Skrygan; B Bartholomé; L Bonafé; N Blau; K Bartholomé
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

2.  Dopa-responsive dystonia with a novel initiation codon mutation in the GCH1 gene misdiagnosed as cerebral palsy.

Authors:  Jae-Hyeok Lee; Chang-Seok Ki; Dae-Seong Kim; Jae-Wook Cho; Kyung-Phil Park; Seonhye Kim
Journal:  J Korean Med Sci       Date:  2011-09-01       Impact factor: 2.153

Review 3.  Genetic [corrected] insights into the causes and classification of [corrected] cerebral palsies.

Authors:  Andres Moreno-De-Luca; David H Ledbetter; Christa L Martin
Journal:  Lancet Neurol       Date:  2012-01-18       Impact factor: 44.182

4.  Occurrence of GCH1 gene mutations in a group of Indian dystonia patients.

Authors:  Tufan Naiya; Amar K Misra; Arindam Biswas; Shyamal K Das; Kunal Ray; Jharna Ray
Journal:  J Neural Transm (Vienna)       Date:  2012-02-29       Impact factor: 3.575

5.  GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs.

Authors:  P R Jarman; O Bandmann; C D Marsden; N W Wood
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-09       Impact factor: 10.154

6.  The role of dopamine receptors in the neurobehavioral syndrome provoked by activation of L-type calcium channels in rodents.

Authors:  Suhail Kasim; Bonita L Blake; Xueliang Fan; Elena Chartoff; Kiyoshi Egami; George R Breese; Ellen J Hess; H A Jinnah
Journal:  Dev Neurosci       Date:  2006       Impact factor: 2.984

Review 7.  Treatment of dystonia.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 8.  Treatment strategies for dystonia.

Authors:  Leslie J Cloud; H A Jinnah
Journal:  Expert Opin Pharmacother       Date:  2010-01       Impact factor: 3.889

Review 9.  Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.

Authors:  B R Thanvi; T C N Lo
Journal:  Postgrad Med J       Date:  2004-08       Impact factor: 2.401

10.  New hypotheses about postural control support the notion that all dystonias are manifestations of excessive brain postural function.

Authors:  Anne J Blood
Journal:  Biosci Hypotheses       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.